31.82
Ultragenyx Pharmaceutical Inc (RARE) 재무 분석
손익 계산서
분기별
*모든 숫자는 백만 단위입니다.
기간 종료일 | 2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
기간 | 3개월 | 3개월 | 3개월 | 3개월 | 3개월 |
Revenues |
19.53%
166.50
|
139.29 | 139.49 | 147.03 | 108.83 |
|
2.78%
274.38
|
282.23 | 271.48 | 263.39 | 274.18 |
Benefits Costs and Expenses |
2.96%
280.50
|
289.06 | 272.71 | 277.77 | 279.06 |
Costs And Expenses |
2.96%
280.50
|
289.06 | 272.71 | 277.77 | 279.06 |
Operating Income/Loss |
24.52%
-107.89
|
-142.94 | -131.99 | -116.36 | -165.35 |
Income/Loss From Continuing Operations Before Tax |
23.88%
-114.00
|
-149.77 | -133.21 | -130.74 | -170.23 |
Income Tax Expense/Benefit |
27.71%
0.947
|
1.31 | 0.303 | 0.858 | 0.455 |
Income/Loss From Continuing Operations After Tax |
23.91%
-114.95
|
-151.08 | -133.52 | -131.60 | -170.68 |
|
23.91%
-114.95
|
-151.08 | -133.52 | -131.60 | -170.68 |
Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
Basic Average Shares |
2.26%
98.46
|
96.29 | 95.49 | 86.58 | 84.29 |
Diluted Average Shares |
2.26%
98.46
|
96.29 | 95.49 | 86.58 | 84.29 |
Basic Earnings Per Share |
25.48%
-1.17
|
-1.57 | -1.40 | -1.52 | -2.03 |
Diluted Earnings Per Share |
25.48%
-1.17
|
-1.57 | -1.40 | -1.52 | -2.03 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
자본화:
|
볼륨(24시간):